Evidence mapPaperPMID 22203459Full record

ArticleAge (Dordrecht, Netherlands)2013

Angiotensin-converting enzyme inhibitors and incidence of mild cognitive impairment. The Italian Longitudinal Study on Aging.

Vincenzo Solfrizzi, Emanuele Scafato, Vincenza Frisardi, Davide Seripa, Giancarlo Logroscino, Patrick G Kehoe, Bruno P Imbimbo, Marzia Baldereschi, Gaetano Crepaldi, Antonio Di Carlo and 7 more

Open access · bronzeAbstract readMulticenter Study
In one paragraph

Article in Age (Dordrecht, Netherlands), 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers, 4 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
20citing papers in PubMed, 4 pooled it
2.0field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

20 citing papers in PubMed, 4 syntheses or guidelines pooled it, 39 citations in OpenAlex.

  1. Pooled it
  2. An evidence-based systematic review of the off-label uses of lisinopril.British journal of clinical pharmacology · 2018
    Pooled it
  3. Pooled it
  4. Pooled it
  5. The Correlation between Two Angiotensin-Converting Enzyme Inhibitor's Concentrations and Cognition.International journal of environmental research and public health · 2022
    Trial
  6. Trial
  7. Article
  8. Article
  9. Review
  10. Article
  11. Review
  12. Possible combined effect of perindopril and Azilsartan in an experimental model of dementia in rats.Saudi pharmaceutical journal : SPJ : the official publication of the Saudi Pharmaceutical Society · 2020
    Article
  13. Article
  14. Review
  15. Angiotensin Converting Enzyme Inhibitors Ameliorate Brain Inflammation Associated with Microglial Activation: Possible Implications for Alzheimer's Disease.Journal of neuroimmune pharmacology : the official journal of the Society on NeuroImmune Pharmacology · 2016
    Article
  16. Review
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors at 6 institutions in 4 countries.

Vincenzo SolfrizziDepartment of Geriatrics, Center for Aging Brain, Memory Unit, University of Bari, Policlinico, Piazza Giulio Cesare, 11, 70124, Bari, Italy. v.solfrizzi@geriatria.uniba.it
Emanuele Scafato
Vincenza Frisardi
Davide Seripa
Giancarlo Logroscino
Patrick G Kehoe
Bruno P Imbimbo
Marzia Baldereschi
Gaetano Crepaldi
Antonio Di Carlo
Lucia Galluzzo
Claudia Gandin
Domenico Inzitari
Stefania Maggi
Alberto Pilotto
Francesco Panza
Italian Longitudinal Study on Aging Working Group
Casa Sollievo della Sofferenza · ITIstituto Superiore di Sanità · ITNational Research Council · ROFrenchay Hospital · GBUniversity of Bari Aldo Moro · ITUniversity of Bristol · GB

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Midlife elevated blood pressure and hypertension contribute to the development of Alzheimer's disease (AD) and overall dementia. We sought to estimate whether angiotensin-converting enzyme inhibitors (ACE-Is) reduced the risk of developing mild cognitive impairment (MCI) in cognitively normal individuals. In the Italian Longitudinal Study on Aging, we evaluated 1,445 cognitively normal individuals treated for hypertension but without congestive heart failure from a population-based sample from eight Italian municipalities with a 3.5-year follow-up. MCI was diagnosed with current clinical criteria. Dementia, AD, and vascular dementia were diagnosed based on DSM-IIIR criteria, NINCDS-ADRDA criteria, and ICD-10 codes. Among 873 hypertension-treated cognitively normal subjects, there was no significant association between continuous exposure to all ACE-Is and risk of incident MCI compared with other antihypertensive drugs [hazard ratio (HR), 0.45, 95% confidence interval (CI), 0.16-1.28]. Captopril exposure alone did not significantly modify the risk of incident MCI (HR, 1.80, 95% CI, 0.39-8.37). However, the enalapril sub-group alone (HR, 0.17, 95% CI, 0.04 -0.84) or combined with the lisinopril sub-group (HR, 0.27, 95% CI, 0.08-0.96), another ACE-I structurally related to enalapril and with similar potency, were associated with a reduced risk of incident MCI. Study duration exposure to ACE-Is as a "class" was not associated with incident MCI in older hypertensive adults. However, within-class differences linked to different chemical structures and/or drug potencies may exist, with a possible effect of the enalapril and lisinopril sub-groups in reducing the risk of incident MCI.

Indexed as

Activities of Daily LivingAgedAged, 80 and overAgingAngiotensin-Converting Enzyme InhibitorsChi-Square DistributionCognitive DysfunctionFemaleHumansHypertensionIncidenceItalyLongitudinal StudiesMaleProportional Hazards ModelsRisk FactorsAngiotensin-Converting Enzyme Inhibitors

Identifiers

PMID22203459
PMCPMC3592955
OpenAlexW2062720767

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.